Enhancing SIV-specific immunity in vivo by PD-1 blockade

Vijayakumar Velu, Kehmia Titanji, Baogong Zhu, Sajid Husain, Annette Pladevega, Lilin Lai, Thomas H. Vanderford, Lakshmi Chennareddi, Guido Silvestri, Gordon J. Freeman, Rafi Ahmed and Rama Rao Amara ()
Additional contact information
Vijayakumar Velu: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Kehmia Titanji: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Baogong Zhu: Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Sajid Husain: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Annette Pladevega: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Lilin Lai: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Thomas H. Vanderford: University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Lakshmi Chennareddi: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Guido Silvestri: University of Pennsylvania School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Gordon J. Freeman: Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Rafi Ahmed: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Rama Rao Amara: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA

Nature, 2009, vol. 458, issue 7235, 206-210

Abstract: Immunity boost in HIV/AIDS Blockade of PD-1 (programmed death-1), a B7/CD28 family immune-receptor molecule that inhibits the immune response to chronic viral infections, is shown to improve anti-viral immune responses in SIV-infected macaques without adverse side effects. The treatment, which used an antibody specific to human PD-1, also prolonged survival. PD-1 blockade was effective without antiretroviral drugs, suggesting that a similar approach might also be effective in HIV/AIDS patients, combined perhaps with drugs or therapeutic vaccination.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature07662 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:458:y:2009:i:7235:d:10.1038_nature07662

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07662

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().